Impact News +++ Charter Communications GAAP EPS of $10.66 beats by $0.60, revenue of $13.53B beats by $20M (SeekingAlpha) +++ CHARTER COMMUNICATIONS Aktie -4,77%

MANNKIND Aktie

>MANNKIND Aktienkurs

3.572 EUR (TradegateBSX)

Ask: 3.611 EUR / 1150 Stück

Bid: 3.532 EUR / 1150 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

MANNKIND Aktie über LYNX handeln

Intraday

1 Jahr

>MANNKIND Performance

1 Woche: -6,3%

1 Monat: +0,3%

3 Monate: +44,8%

6 Monate: -31,7%

1 Jahr: -1,6%

laufendes Jahr: -32,2%

>MANNKIND Aktie

Profil:

MannKind Corporation is a biopharmaceutical company focused on developing and commercializing innovative inhaled therapies and devices for patients with cardiometabolic and orphan lung diseases, including diabetes, pulmonary hypertension, and fluid o..
>Volltext..

Insiderhandel:

>MANNKIND Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>MANNKIND Peer Group

Gesundheit, Lungenerkrankungen & -behandlung/ Asthma, Endokrine Erkrankungen (Hormonstörungen), Nierenerkrankungen & -behandlung, Stoffwechselerkrankungen (Diabetes/ Adipositas)
>Alle Branchen..

>MANNKIND Chart & Kurs - NASDAQ

>MANNKIND News

24.07.26 - 13:00	MannKind shares rise on announcing $50M private placement financing (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

24.07.26 - 12:39	MannKind Announces $50 Million Private Placement (GlobeNewswire EN)
	MannKind Announces $50 Million Private Placement...

24.07.26 - 12:33	MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease (GlobeNewswire EN)
	MannKind announces FDA approval of Furoscix ReadyFlow™, the first & only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema...

21.07.26 - 02:12	What This MannKind Filing Reveals About Three Years of Underperformance (Fool)
	Performance-based RSUs vested at 83% of target, reflecting MannKind's stock performance against industry benchmarks. Singh retains ~479,000 shares valued at $1.96 million....

21.07.26 - 01:48	What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk (Fool)
	Binder's disposition followed vesting of performance-based awards tied to the company's total shareholder return relative to the Russell 3000 Pharmaceutical & Biotechnology Index....

21.07.26 - 01:36	What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million (Fool)
	This disposition was tied to vesting of performance-based RSUs at 83% of the target....

21.07.26 - 01:24	Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk (Fool)
	Tross disposed of 65,808 shares to cover tax withholding from a vested performance award, retaining over 1 million shares in the company....

20.07.26 - 03:24	Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares? (Fool)
	Castagna retains 2.4 million shares after the non-discretionary sale tied to RSU vesting, maintaining substantial alignment with the biopharmaceutical company....

18.07.26 - 07:01	Insiderhandel: Aufsichtsrat verkauft Aktien von MannKind im Wert von 213089 USD (Insiderkauf)
	Binder, Steven B. - Aufsichtsrat - Tag der Transaktion: 2026-07-17...

18.07.26 - 07:01	Insiderhandel: EVP Genl Counsel & Secretary verkauft Aktien von MannKind im Wert von 97641 USD (Insiderkauf)
	Thomson, David - Vorstand - Tag der Transaktion: 2026-07-17...

23.06.26 - 15:03	MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D (GlobeNewswire EN)
	MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D...

06.06.26 - 01:36	Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind′s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems (GlobeNewswire EN)
	Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use...

03.06.26 - 12:06	MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF (GlobeNewswire EN)
	MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2...

29.05.26 - 20:03

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval (GlobeNewswire EN)

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes....

29.05.26 - 19:42	MannKind gains FDA nod to expand inhaled insulin for children (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.05.26 - 19:01	US FDA approves MannKind′s inhaled insulin for children (Reuters EN)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

29.05.26 - 18:33	MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes (GlobeNewswire EN)
	MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents Aged 6 and Older Living with Diabetes...

27.05.26 - 22:03	MannKind to Present at Jefferies Global Healthcare Conference (GlobeNewswire EN)
	DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET....

27.05.26 - 15:09	MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems (GlobeNewswire EN)
	MANNKIND TO SHOWCASE NEW DATA AT ADA 2026 ADVANCING UNDERSTANDING OF INHALED INSULIN (AFREZZA®) IN PEDIATRIC CARE, PREGNANCY AND USE WITH AID SYSTEMS...

14.05.26 - 07:01	Insiderhandel: Aufsichtsrat verkauft Aktien von MannKind im Wert von 55733 USD (Insiderkauf)
	Binder, Steven B. - Aufsichtsrat - Tag der Transaktion: 2026-05-12...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Idiot heißt einer, insofern Eigenheit in ihm ist. - Georg Wilhelm Friedrich Hegel

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram